IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v448y2007i7149d10.1038_nature05957.html
   My bibliography  Save this article

Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo

Author

Listed:
  • Päivi Lindholm

    (Institute of Biotechnology, P.O. Box 56, Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland)

  • Merja H. Voutilainen

    (Faculty of Pharmacy, P.O. Box 56,Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland)

  • Juha Laurén

    (Institute of Biotechnology, P.O. Box 56, Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland
    Present addresses: Department of Neurology, Yale University School of Medicine, P.O. Box 208018, New Haven, Connecticut 06520, USA (J.L.); Department of Pharmacology, CARIM, University of Maastricht, P.O. Box 616, Maastricht, 6200 MD, The Netherlands (S.J.).)

  • Johan Peränen

    (Institute of Biotechnology, P.O. Box 56, Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland)

  • Veli-Matti Leppänen

    (Institute of Biotechnology, P.O. Box 56, Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland)

  • Jaan-Olle Andressoo

    (Institute of Biotechnology, P.O. Box 56, Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland)

  • Maria Lindahl

    (Institute of Biotechnology, P.O. Box 56, Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland)

  • Sanna Janhunen

    (Faculty of Pharmacy, P.O. Box 56,Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland
    Present addresses: Department of Neurology, Yale University School of Medicine, P.O. Box 208018, New Haven, Connecticut 06520, USA (J.L.); Department of Pharmacology, CARIM, University of Maastricht, P.O. Box 616, Maastricht, 6200 MD, The Netherlands (S.J.).)

  • Nisse Kalkkinen

    (Institute of Biotechnology, P.O. Box 56, Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland)

  • Tõnis Timmusk

    (Institute of Biotechnology, P.O. Box 56, Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland
    Tallinn University of Technology, Akadeemia tee 15, 19086 Tallinn, Estonia)

  • Raimo K. Tuominen

    (Faculty of Pharmacy, P.O. Box 56,Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland)

  • Mart Saarma

    (Institute of Biotechnology, P.O. Box 56, Viikki Biocenter, University of Helsinki, FIN-00014, Helsinki, Finland)

Abstract

Neuronal rescue The drugs currently available for Parkinson's disease patients generally treat only the symptoms, and do not prevent the degeneration and death of dopaminergic neurons in the brain, the cause the motor defects associated with the disease. Treatment with glial cell line-derived neurotrophic factor (GDNF) has had limited success, but there are safety concerns. Lindholm et al. report the discovery and purification of a new neurotrophic factor, called conserved dopamine neurotrophic factor (CDNF), that can also prevent degeneration of dopaminergic neurons in a rat model of Parkinson's disease. In rats with established Parkinson's disease, CDNF even induces some recovery of dopaminergic function. A paper in last week's Nature identified calcium antagonists as a possible means of rejuvenating dopaminergic neurons, so it seems that at last there are several lines of research that might one day lead to genuinely effective antiparkinsons drugs.

Suggested Citation

  • Päivi Lindholm & Merja H. Voutilainen & Juha Laurén & Johan Peränen & Veli-Matti Leppänen & Jaan-Olle Andressoo & Maria Lindahl & Sanna Janhunen & Nisse Kalkkinen & Tõnis Timmusk & Raimo K. Tuominen &, 2007. "Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo," Nature, Nature, vol. 448(7149), pages 73-77, July.
    • Handle: RePEc:nat:nature:v:448:y:2007:i:7149:d:10.1038_nature05957
    DOI: 10.1038/nature05957
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/nature05957
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/nature05957?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:448:y:2007:i:7149:d:10.1038_nature05957. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.